Increased plasma levels of the methylglyoxal in patients with newly diagnosed type 2 diabetes 初诊2型糖尿病患者血浆甲基乙二醛水平升高

<jats:title>Abstract</jats:title><jats:sec><jats:title>Background</jats:title><jats:p>Methylglyoxal (<jats:styled-content style="fixed-case">MG</jats:styled-content>) is a reactive‐dicarbonyl that is thought to contribute to the development of diabetes either as a precursor for advanced glycation end products or as a direct toxin. The present study was designed to determine plasma <jats:styled-content style="fixed-case">MG</jats:styled-content> level in patients with newly diagnosed type 2 diabetes mellitus (<jats:styled-content style="fixed-case">T2DM</jats:styled-content>) and to evaluate the relationship between <jats:styled-content style="fixed-case">MG</jats:styled-content> and other parameters, such as oxidative stress and metabolic indices.</jats:p></jats:sec><jats:sec><jats:title>Methods</jats:title><jats:p>Methylglyoxal was measured by high‐performance liquid chromatographic/tandem mass spectrometry in plasma from 48 subjects with newly diagnosed <jats:styled-content style="fixed-case">T2DM</jats:styled-content>. The relationship between two variables was analyzed using Spearman's correlation analysis. Multiple stepwise linear regression analysis was used to assess the association of plasma <jats:styled-content style="fixed-case">MG</jats:styled-content> and other parameters.</jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p>Plasma <jats:styled-content style="fixed-case">MG</jats:styled-content> level in patients with newly diagnosed <jats:styled-content style="fixed-case">T2DM</jats:styled-content> (65.2 ± 19.2 ng/mL) were significantly higher than that in control individuals (40.1 ± 11.1 ng/mL, <jats:italic>P</jats:italic> < 0.05). The plasma level of <jats:styled-content style="fixed-case">MG</jats:styled-content> was positively correlated with the glycosylated hemoglobin A1c (<jats:styled-content style="fixed-case">HbA1c</jats:styled-content>, r = 0.670, <jats:italic>P</jats:italic> < 0.01) and malondialdehyde (<jats:styled-content style="fixed-case">MDA</jats:styled-content>, r = 0.694, <jats:italic>P</jats:italic> < 0.01). Multiple linear regression analysis revealed that both HbA1c and <jats:styled-content style="fixed-case">MDA</jats:styled-content> are significant independent determinants of plasma <jats:styled-content style="fixed-case">MG</jats:styled-content> level.</jats:p></jats:sec><jats:sec><jats:title>Conclusions</jats:title><jats:p>These findings suggest that increased plasma <jats:styled-content style="fixed-case">MG</jats:styled-content> level is associated with the elevation of <jats:styled-content style="fixed-case">HbA1c</jats:styled-content> and <jats:styled-content style="fixed-case">MDA</jats:styled-content> in newly diagnosed <jats:styled-content style="fixed-case">T2DM</jats:styled-content> patients.</jats:p></jats:sec>